directors selling (large), page-5

G'day Alpha

I think that expectations have been a little optimistic, the delay(s) in approvals have tended to set time at large.

But the market for the product is still there, and increasing. Despite the lack of updated CDC guidelines for QFT-Gold in the US hospitals, clinics even states (California & Hawaii) have started to implement the product.

The transition wont happen overnight, but once implemented its a matter of ramping up the sales.

Recently published results of clinical trials have shown QFT-Gold to be the superior diagnostic for active TB, this was not the stated goal of CST, they wanted to capture the latent TB market. Now we could be looking at the active TB market.

Japan (Nicherie) have set year 1 sales goal of QFT at 300M yen - and we are always told how conservative they are. With the recent implementation of the Jap TB Law making TB testing mandatory (for some groups of the population) its now just a waiting game to see how the CST sales go.

Always UP, but how much is the question.